secwatch.observer — SEC 8-K summary
======================================

Issuer:     Relay Therapeutics, Inc. (RLAY)
CIK:        0001812364
Form:       8-K
Filed at:   2024-08-06T23:59:59+00:00
Accession:  0000950170-24-091802
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Relay Therapeutics Q2 net loss $0.69/sh; cash $688M; new preclinical programs unveiled
--------------------------------------------------------------------------------

- Q2 net loss $92.2M ($0.69/share) vs $98.5M ($0.81) in Q2 2023.
- Cash, equivalents & investments $688.4M; expected to fund operations into H2 2026.
- Announced 3 new preclinical programs: vascular malformations (PI3Kα), Fabry disease (non-inhibitory chaperone), NRAS-selective inhibitor.
- Initiated Pfizer collaboration for RLY-2608 + fulvestrant + atirmociclib triplet; clinical start by end of 2024.
- RLY-2608+fulvestrant doublet data update in Q4 2024 with ~100 patients safety database and ~60 at 600mg BID.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1812364/000095017024091802/0000950170-24-091802-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1812364/000095017024091802/rlay-20240806.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-091802

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer